Swedish Orphan Biovitrum AB (publ)

Chart & Performance

D1W1MN

P/E

44.25

P/S

4.82

EPS

7.01

Div Yield, %

0.00%

Shrs. gr., 5y

3.79%

Rev. gr., 5y

19.34%

Revenues

22.12b

+17.74%

Net income

2.41b

-8.68%

CFO

4.47b

-4.18%

Earnings

Feb 06, 2025

Profile

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. It offers Alprolix for haemophilia B; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company It also provides other products, such as Akynzeo, Aloxi, Ammonul, Betapred, Caphosol, Fibclot, IVheBex, and Willfact. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to develop pegcetacoplan for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.

URL

https://www.sobi.com/

IPO date

Sep 15, 2006

Employees

1,793

Domiciled in

Incorporated in

Valuation

Order:

Title SEK in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title SEK in thousands, except ratios and share amounts	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12	2014‑12
Income
Revenues	22,123,000 17.74%	18,790,000 21.00%	15,529,000 1.76%
Cost of revenue	17,952,000	14,977,000	11,772,000
Unusual Expense (Income)
NOPBT	4,171,000	3,813,000	3,757,000
NOPBT Margin	18.85%	20.29%	24.19%
Operating Taxes	546,000	683,000	616,000
Tax Rate	13.09%	17.91%	16.40%
NOPAT	3,625,000	3,130,000	3,141,000
Net income	2,409,000 -8.68%	2,638,000 -1.53%	2,679,000 -17.44%
Dividends
Dividend yield
Proceeds from repurchase of equity	6,129,000	89,000
BB yield	-7.04%	-0.13%
Debt
Debt current	8,961,000	5,929,000	1,882,000
Long-term debt	11,840,000	3,505,000	9,385,000
Deferred revenue			234,000
Other long-term liabilities	2,861,000	4,146,000	3,834,000
Net debt	19,755,000	7,952,000	10,023,000
Cash flow
Cash from operating activities	4,470,000	4,665,000	5,470,000
CAPEX	(407,000)	(1,477,000)	(370,000)
Cash from investing activities	(21,904,000)	(1,477,000)	(367,000)
Cash from financing activities	17,012,000	(2,991,000)	(4,474,000)
FCF	2,863,000	3,281,000	3,776,000
Balance
Cash	904,000	1,361,000	1,045,000
Long term investments	142,000	121,000	199,000
Excess cash		542,500	467,550
Stockholders' equity	17,315,000	16,314,000	13,324,000
Invested Capital	57,213,000	38,844,500	37,405,450
ROIC	7.55%	8.21%	8.37%
ROCE	6.53%	8.83%	9.06%
EV
Common stock shares outstanding	325,968	312,455	310,729
Price	267.00 23.78%	215.70 16.53%	185.10 11.44%
Market cap	87,033,362 29.14%	67,396,595 17.18%	57,515,929 11.12%
EV	106,788,362	75,348,595	67,604,929
EBITDA	7,340,000	6,232,000	5,763,000
EV/EBITDA	14.55	12.09	11.73
Interest	1,111,000	458,000	419,000
Interest/NOPBT	26.64%	12.01%	11.15%